🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

47 results for “Essen” Clear

  1. 60 mg ulixacaltamide

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 3 small molecule active

    1 trial

  2. ANAGRELIDE HYDROCHLORIDE MONOHYDRATE, PEGINTERFERON ALFA-2A, MK-3543, BUSULFAN, MK-3543, RUXOLITINIB, MK-3543, MK-3543, RUXOLITINIB, PEGINTERFERON ALFA-2A

    Merck Sharp and Dohme

    Essential Thrombocythemia patients who have an inadequate response to or are intolerant of hydroxyurea

    phase 3 small molecule active

    1 trial

  3. Amlodipine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Essential Hypertension

    phase 3 small molecule active

    1 trial

  4. Anagrelide Hydrochloride

    Takeda

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  5. Azilsartan medoxomil and chlorthalidone

    Takeda

    Essential Hypertension

    phase 3 small molecule completed

    4 trials

  6. Azilsartan medoxomil/placebo

    Takeda

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  7. CPI-0610, CPI-0610

    Novartis Pharmaceuticals

    Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)

    phase 3 small molecule active

    1 trial

  8. CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx

    Cardiol Therapeutics

    Recurrent Pericarditis

    phase 3 small molecule active

    1 trial

  9. DANAZOL , BUSULFAN , -, POMALIDOMIDE , FEDRATINIB, RUXOLITINIB, PEGFILGRASTIM , HYDROXYCARBAMIDE , PEGINTERFERON ALFA-2A , -

    Celgene Europe Limited

    Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis

    phase 3 small molecule active

    1 trial

  10. Fimasartan and Rosuvastatin

    Yung NA

    Essential Hypertension, Dyslipidemia

    phase 3 small molecule completed

    1 trial

  11. MK-3543, HYDROXYCARBAMIDE , Placebo for hydroxycarbamide, MK-3543, MK-3543, MK-3543, Placebo for Bomedemstat

    Merck Sharp and Dohme

    Essential thrombocythemia

    phase 3 small molecule active

    1 trial

  12. MK-3543, MK-3543, MK-3543, MK-3543

    Merck Sharp and Dohme

    Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis)

    phase 3 small molecule active

    1 trial

  13. P1101

    PharmaEssentia

    Polycythemia Vera (PV)

    phase 3 small molecule completed

    1 trial

  14. Ropeginterferon alfa-2b

    PharmaEssentia

    Primary Myelofibrosis

    phase 3 mab active

    1 trial

  15. SPD422 (anagrelide hydrochloride)

    Takeda

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  16. Solution for Injection, subcutaneous Use, IMCIVREE 10 mg/ml solution for injection

    Lacuna Pharma Pty Ltd

    Improper function of certain messenger materials in the body that control body weight and hunger in people

    phase 3 small molecule active

    1 trial

  17. TAK-536CCB

    Takeda

    Grade I or II Essential Hypertension

    phase 3 small molecule completed

    1 trial

  18. TAK-536TCH tablet

    Takeda

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  19. olmesartan alone or in combination with hydrochlorothiazide

    Pfizer

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  20. 10 mg PRAX-114, 20 mg PRAX-114, and Placebo

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule terminated

    1 trial

  21. 100 mg PRAX-944

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  22. CX-8998

    Jazz Pharmaceuticals Ireland Limited

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  23. Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

    GlaxoSmithKline

    Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

    phase 2 other active

    1 trial

  24. JZP385

    Jazz Pharmaceuticals Ireland Limited

    Essential Tremor

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources